Alternative weight loss treatments
CoolSculpting is a revolutionary non-surgical weight loss treatment that is clinically proven to target problem areas that dieting and exercising may not be able to tackle; love handles, muffin tops, man boobs and bingo wings. Both men and women can benefit from evasive and pain-free CoolScuplting treatments, which are so simple they can be carried out in one to two hours on a walk-in walk-out basis.
CoolScuplting was developed by a group of Harvard scientists and it works by freezing a specific area of fat cells. The temperature at which the area is chilled to damages the fat cells and triggers their natural death, but leaves the rest of the surrounding nerves and tissue unharmed. The body’s metabolic system then removes the fat cells and prevents them from returning in that area.
Face and Body is a non-cosmetic surgical clinic and the first to offer the CoolSculpting procedure in Scotland, UK. According to the clinic, each individual CoolSculpting treatment permanently reduces fat by 20 percent and has a 100 percent success rate. Results start to be visible after receiving the treatment for three weeks and it becomes most noticeable four months in the treatment cycle.
Dr. Victoria Dobbie, the owner of the Face and Body clinic, said: “The results are astonishing. This is a major breakthrough in non-evasive fat reduction treatments. We have been fully booked since we launched the service and the feedback we have had has been incredible.”
The science behind CoolSculpting:
CoolSculpting treatments are so simple they can be done during lunch breaks:
A combined treatment of ultrasound therapy and massage, Med Contour can reportedly result in instant fat loss. Described as a body shaping system as opposed to an answer to weight loss, Med Contour treatments shape and smooth the body to reduce the appearance of cellulite.
Rather than being targeted at organic body fat which can only be treated with a diet and fitness overhaul, Med Contour procedures focus specifically on fatty tissues. The ultrasound aspect of the therapy encourages fat cell mobility, therefore making the body metabolise, drain and reabsorb excess fluids. The zonal lymphatic massage then drains toxins and excessive fluids from the patient’s body.
Med Contour is currently available in the UK at the Landmark Lifestyle clinic on Harley Street. Warren Vaheeswaran, the Director of UK Operations at Landmark, said about the treatment: “Med Contour is a great body shaping alternative for those who do not want an invasive surgical procedure. It is ideal for the average person who wants to target a specific problem area. My patients have seen excellent results of 2cms to 7cms in just an hour, with longer lasting results after a few treatments.”
“We have treated nearly 1000 people in eight months and we have had phenomenal success. However, we need to emphasis this isn’t a weight loss programme but a fat loss drainage programme,” Vaheeswaran added.
As well as a cellulite and fat reducing treatment, Med Contour has a number of alternative benefits. These include pain relief from muscular aches and spasms, improving blood circulation and reducing post-operative pain associated with treatments such as liposuction.
Med Contour treatments:
Iyashi Dômes come with an incredible claim; that users can burn up to 600 calories after just one hour. Dubbed as a “new experience in well-being”, Iyashi Dômes are of Japanese descent and have arrived in the UK as a revolutionary fat loss and detox treatment. As part of an Iyashi Dôme treatment, users lie down on a wooden bed surrounded by a carbon dome which uses infrared rays to heat up the body. The heat encourages the body to sweat, seeing users sweat out toxins and break down fat.
In terms of fat and weight loss, sessions in an Iyashi Dôme can help to enhance user’s silhouettes, help them to tone up and reduce visible signs of cellulite. Although the other benefits of Iyashi treatments are not directly linked to weight loss, they include detoxification, rejuvenation and the elimination of toxins, all of which can assist with anti-aging. In just one Iyashi Dôme session, users produce them same amount of sweat as they would during a 20km run and up to 1,200ml of perspiration can be lost.
The Iyashi Dôme has just been launched for the first time in London, at the MyDetoxDiet clinic. To enhance the Iyashi Dôme treatments, the clinic has a developed a range of detox plans and diets which can enhance the results.
Commenting on the services offered at MyDetoxDiet, the co-founders, Ilona Wesle and Susanne Kollner, said: “Our Detox allows users to purge their system through a combination of infrared Dôme sessions and a low fat, salt free diet. The results will speak for themselves; they will no longer feel sluggish, they will be sleeping better, be healthier, lose pounds and inches and finally feel revitalised.”
The challenges to vaccine distribution affecting everyone
While it is comforting to know that vaccines against COVID-19 are showing remarkable efficacy, the world still faces intractable challenges with vaccine distribution. Specifically, the sheer number of vaccines required and the complexity of global supply chains are sure to present problems we have neither experienced nor even imagined.
Current projections estimate that we could need 12-15 billion doses of vaccine, but the largest vaccine manufacturers produce less than half this volume in a year. To understand the scale of the problem, imagine stacking one billion pennies – you would have a stack that is 950 miles high. Now, think of that times ten. This is a massive problem that one nation can’t solve alone.
Even if we have a vaccine – can we make enough? Based on current projections, Pfizer expects to produce up to 1.3 billion doses this year. Moderna is working to expand its capacity to one billion units this year. Serum Institute of India, the world’s largest vaccine producer, is likely to produce 60% of the 3 billion doses committed by AstraZeneca, Johnson & Johnson and Sanofi. This leaves us about 7 billion doses short.
Expanding vaccine production for most regions in the world is complicated and time-consuming. Unlike many traditional manufacturing operations that can expand relatively quickly and with limited regulation, pharmaceutical production must meet current good manufacturing practice (CGMP) guidelines. So, not only does it take time to transition from R&D to commercial manufacturing, but it could also take an additional six months to achieve CGMP certification.
The problem becomes even more complex when considering the co-products required. Glass vials and syringes are just two of the most essential co-products needed to produce a vaccine. Last year, before COVID-19, global demand for glass vials was 12 billion. Even if it is safe to dispense ten doses per vial, there is certain to be significant pressure on world supply of the materials needed to package and distribute a vaccine.
It is imperative drug manufacturers and their raw material suppliers have clear visibility of production plans and raw material availability if there is any hope of optimizing scarce resources and maximising production yield.
It is widely known by now that temperature is a critical factor for the COVID-19 vaccine. Even the regions with the most developed logistics infrastructures and resources needed to support a cold-chain network are sure to struggle with distribution.
For the United States alone, State and local health agencies have determined distribution costs will exceed $8.4 billion, including $3 billion for workforce recruitment and training; $1.2 billion for cold-chain, $1 billion vaccination sites and $0.5 billion IT upgrades.
The complexity of the problem increases further when considering countries such as India that do not have cold-chain logistics networks that meet vaccine requirements. Despite India’s network of 28,000 cold-chain units, none are capable of transporting vaccines below -25°Celsius. While India’s Serum Institute has licensed to manufacture AstraZeneca’s vaccine, which can reportedly be stored in standard refrigerated environments, even a regular vaccine cold chain poses major challenges.
Furthermore, security will undoubtedly become a significant concern that global authorities must address with a coordinated solution. According to the Pharmaceutical Security Institute, theft and counterfeiting of pharmaceutical products rose nearly 70% over the past five years. As with any valuable and scarce product, counterfeits will emerge. Suppliers and producers are actively working on innovative approaches to limit black-market interference. Corning, for example, is equipping vials with black-light verification to curb counterfeiting.
Clearly, this is a global problem that will require an unprecedented level of collaboration and coordination.
Disconnected information systems
While it is unreasonable to expect every country around the world will suddenly adopt a standard technology that would provide immediate, accurate and available information for everyone, it is not unreasonable to think that we can align on a standard taxonomy that can serve as a Rosetta Stone for collaboration.
A shared view of the situation (inventory, raw materials, delivery, defects) will provide every nation with the necessary information to make life-saving decisions, such as resource pooling, stock allocations and population coverage.
By allowing one central authority, such as the World Health Organization, to organize and align global leaders to a single collaboration standard, such as GS1, and a standard sharing protocol, such as DSCSA, then every supply chain participant will have the ability to predict, plan and execute in a way that maximises global health.
Political influence and social equality
As if we don’t have enough stress and churn in today’s geopolitical environment, we must now include the challenge of “vaccine nationalism.” While this might not appear to be a supply chain problem, per se, it is a critical challenge that will hinge on supply chain capabilities.
In response to the critical supply issues the world experienced with SARS-CoV-2, the World Health Organization, Gavi, the Vaccine Alliance and the Coalition for Epidemic Preparedness Innovations (CEPI) formed Covax: a coalition dedicated to equitable distribution of 2 billion doses of approved vaccines to its 172 member countries. Covax is currently facilitating a purchasing pool and has made commitments to buy massive quantities of approved vaccines when they become available.
However, several political powerhouse countries, such as the United States and Russia, are not participating. Instead, they are striking bilateral deals with drug manufacturers – essentially, competing with the rest of the world to secure a national supply. Allocating scarce resources is never easy, but when availability could mean the difference between life and death, it becomes almost impossible.
Global production, distribution and social equality present dependent yet conflicting realities that will demand global supply chains provide complete transparency and an immutable chain of custody imperative to vaccine distribution.
The technology is available today – we just need to use it. We have the ability to track every batch, pallet, box, vile and dose along the supply chain. We have the ability to know with absolute certainty that the vaccine is approved, where and when it was manufactured, how it was handled and whether it was compromised at any point in the supply chain. Modern blockchain technologies should be applied so that every nation, institution, regulator, doctor and patient can have confidence in knowing that they are making an impact in eradicating COVID-19.